Methods and systems for treating tumors

Patent metadata

Field	Value
Publication number	US-2016367672-A1
Application number	US-201515122352-A
Country	US
Kind code	A1
Filing date	Mar 3, 2015
Priority date	Mar 3, 2014
Publication date	Dec 22, 2016
Grant date	—

Abstract

The invention relates methods and systems of using a nanoparticle and near infrared radiation to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of a condition in a subject. The invention also relates to compositions comprising a nanoparticle. Conditions treatable with the methods systems and compositions include but are not limited to various tumors.

First claim

1 . A method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising:
providing a nanoparticle; administering a therapeutically effective amount of the nanoparticle to the subject; applying near infrared radiation (NIR) to the subject to induce hyperthermia, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject.

2 . The method of claim 1 , wherein the condition is brain tumor, glioma, glioblastoma, and/or glioblastoma multiforme (GBM).

3 . The method of claim 1 , wherein the nanoparticle is a nanotube, nanorod, nanoshell, nanocage, nanosphere, nanofiber, or nanowire, or a combination thereof.

4 . The method of claim 1 , wherein the nanoparticle is made of carbon, gold, selenium, copper, platinum, or a combination thereof.

5 . The method of claim 1 , wherein the nanoparticle is administered intratumorally, intracranially, intraventricularly, intrathecally, epidurally, intradurally, intravascularly, intravenously, intraarterially, intramuscularly, subcutaneously, intraperitoneally, orally, intranasally, or via inhalation.

6 . The method of claim 1 , wherein the nanoparticle is administered at about 0.001 to 0.01, 0.01 to 0.1, 0.1 to 0.5, 0.5 to 5, 5 to 10, 10 to 20, 20 to 50, 50 to 100, 100 to 200, 200 to 300, 300 to 400, 400 to 500, 500 to 600, 600 to 700, 700 to 800, 800 to 900, or 900 to 1000 ng per mm 3 tumor.

7 . The method of claim 1 , wherein the nanoparticle is administered at about 0.001 to 0.01, 0.01 to 0.1, 0.1 to 0.5, 0.5 to 5, 5 to 10, 10 to 20, 20 to 50, 50 to 100, 100 to 200, 200 to 300, 300 to 400, 400 to 500, 500 to 600, 600 to 700, 700 to 800, 800 to 900, or 900 to 1000 μg.

8 . The method of claim 1 , wherein the nanoparticle is administered once, twice, three or more times.

9 . The method of claim 1 , wherein the nanoparticle is provided in a pharmaceutical composition.

10 . The method of claim 9 , wherein the pharmaceutical composition further comprises a chemotherapeutic agent.

11 . The method of claim 1 , wherein NIR is applied at about 0.001 to 0.01, 0.01 to 0.1, 0.1 to 0.5, 0.5 to 5, 5 to 10, 10 to 20, 20 to 50, 50 to 100, 100 to 200, 200 to 300, 300 to 400, 400 to 500, 500 to 600, 600 to 700, 700 to 800, 800 to 900, or 900 to 1000 W/cm 2 .

12 . The method of claim 1 , wherein NIR is applied for about 0.001 to 0.01, 0.01 to 0.1, 0.1 to 0.5, 0.5 to 5, 5 to 10, 10 to 20, 20 to 50, 50 to 100, 100 to 200, 200 to 300, 300 to 400, 400 to 500, 500 to 600, 600 to 700, 700 to 800, 800 to 900, or 900 to 1000 minutes.

13 . The method of claim 1 , wherein NIR is applied once, twice, three or more times.

14 . The method of claim 1 , further comprising administering an NIR-emitting device into a tumor, near a tumor, into a tumor resection cavity, near a resected tumor, or near a tumor cell.

15 . The method of claim 14 , wherein the NIR-emitting device comprises an NIR-emitting light source.

16 . The method of claim 14 , wherein administering the NIR-emitting device is via implanting the NIR device.

17 . The method of claim 14 , wherein administering the NIR-emitting device is via a transcatheter procedure.

18 . The method of claim 14 , wherein administering the NIR-emitting device comprises placing the NIR-emitting device on the tip of a catheter and using the catheter to administer the NIR-emitting device.

19 . The method of claim 14 , wherein administering the NIR-emitting device comprises placing the NIR-emitting device as a balloon on the tip of a catheter and using the catheter to administer the NIR-emitting device.

20 . A system for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising a quantity of a nanoparticle and a means for applying NIR.

21 . The system of claim 20 , further comprising a chemotherapeutic agent.

22 . The system of claim 20 , wherein the means for applying NIR is an NIR-emitting device.

23 . The system of claim 22 , wherein the NIR-emitting device comprises an NIR-emitting light source.

24 . The system of claim 22 , further comprising a catheter, wherein the NIR-emitting device is placed on the tip of the catheter.

25 . The system of claim 22 , further comprising a catheter, wherein the NIR-emitting device is placed as a balloon on the tip of the catheter.

Assignees

• Univ Southern California

Inventors

• Chen Thomas C
• Hofman Florence M
• Santos Tiago A R T S

Classifications

• A61B18/04

  by heating (by applying electromagnetic radiation A61B18/18) · CPC title

• A61B2018/0022

  Balloons · CPC title

• A61K41/0052 Primary

  Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy · CPC title

• A61N2005/0612

  using probes penetrating tissue; interstitial probes · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title